Tesamorelin (10mg vials)

Description

Tesamorelin

Swipe right to view full table →

Save over 70%!

Product Format	10mg vials
Vial Size	10mg
Vial Capacity	3 mL
Box Combinations	20mg, 50mg, 100mg, 200mg
Multi-vial Purity	99.81%
Endotoxin Screening	PASSED
Heavy Metals Screening	PASSED
Purity Screening	PASSED
Independently Tested	YES

Research Studies

(for educational purposes only)

Study 1: Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS

Authors: Knoop A, Thomas A, Fichant E, Delahaut P, Schänzer W, Thevis M.

Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC4830873/

Scientific Findings

This study reports the development and validation of a qualitative method for the simultaneous detection of four GHRHs, including Tesamorelin, in human plasma. The method employs immunoaffinity purification using a polyclonal GHRH antibody followed by nano-ultrahigh performance liquid chromatography-high resolution/high accuracy tandem mass spectrometry (LC-HRMS/MS). The in vitro experiments demonstrated the metabolic stability of Tesamorelin. The method was validated for specificity, linearity, recovery, lower limit of detection, imprecision, and ion suppression/enhancement effects, proving its fitness for purpose in sports drug testing.

Plain English Interpretation

Researchers developed a highly sensitive method to detect Tesamorelin and other growth hormone-releasing hormones (GHRHs) in human plasma. This new test uses a combination of immunoaffinity purification and liquid chromatography-mass spectrometry to identify these substances with high accuracy. The study also investigated the stability of Tesamorelin in a laboratory setting and found it to be metabolically stable. This is significant for anti-doping applications as it provides a reliable method for detecting the use of these banned substances in athletes.

Study 2: Structural basis for activation of the growth hormone-releasing hormone receptor

Authors: Zhou F, Li JJ, Li XC, Jiang Y, Yang DH, Chen LN, Xu HE, Li MJ, Li XF.

Source: https://www.nature.com/articles/s41467-020-18945-0

Scientific Findings

This study elucidates the cryo-electron microscopy structure of the human growth hormone-releasing hormone receptor (GHRHR) in complex with its endogenous ligand GHRH and the stimulatory G protein (Gs). The structure reveals that GHRH binds to a novel site within the transmembrane domain of the receptor, which is distinct from the binding mode of other class B GPCRs. The study identifies key residues for GHRH binding and receptor activation, providing a structural basis for understanding the mechanism of action of GHRH and its analogues like Tesamorelin. This structural information is invaluable for the rational design of new therapeutic agents targeting the GHRHR.

Plain English Interpretation

Scientists have created a 3D map of the receptor in our bodies that Tesamorelin and other similar hormones bind to. This map, obtained using a technique called cryo-electron microscopy, shows exactly how the hormone ‘docks’ with the receptor to activate it. This is a crucial discovery because it helps us understand the fundamental mechanism of how Tesamorelin works at a molecular level. This knowledge can be used to design new and better drugs that target this receptor for various medical conditions.

Study 3: Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD

Authors: Fourman LT, Billingsley JM, Agyapong G, Ho Sui SJ, Feldpausch MN, Purdy J, Zheng I, McClure CM, Corey KE, Torriani M, Kleiner DE, Hadigan CM, Chung RT, Grinspoon SK.

Source: https://insight.jci.org/articles/view/140134

Scientific Findings

This study investigated the effects of Tesamorelin on hepatic transcriptomic and proteomic signatures in patients with HIV-associated non-alcoholic fatty liver disease (NAFLD). The researchers performed RNA sequencing on liver biopsies and proteomic analysis of plasma samples from patients treated with Tesamorelin or placebo. The results showed that Tesamorelin treatment was associated with downregulation of hepatic gene sets involved in inflammation, tissue repair, and cell division. Furthermore, a targeted proteomic analysis revealed that Tesamorelin modulated the levels of several plasma proteins that are linked to these pathways. These findings provide a molecular basis for the observed clinical benefits of Tesamorelin in reducing liver fat and fibrosis in this patient population.

Plain English Interpretation

In this study, researchers investigated how Tesamorelin affects the liver in people with HIV-associated fatty liver disease. They analyzed liver tissue and blood samples from patients treated with Tesamorelin and found that the drug changed the activity of genes involved in inflammation, tissue repair, and cell division. Specifically, Tesamorelin reduced the activity of genes that cause inflammation and scarring in the liver. This study provides important insights into the molecular mechanisms by which Tesamorelin improves liver health in this patient population.

Research Use Only. Not for use in diagnostic tests.

This product is solely intended for research purposes as a chemical compound. Its designation permits its use exclusively for in-vitro testing and laboratory experimentation. All information regarding this product provided on our website is purely educational. By law, any form of bodily introduction of this product into humans or animals is strictly prohibited. It should only be handled by professionals who are licensed and qualified. This product is neither a drug, food, nor cosmetic, and must not be misrepresented, misused, or mislabeled as such.